Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial von Zamarin, Dmitriy, Walderich, Sven, Holland, Aliya, Zhou, Qin, Iasonos, Alexia E, Torrisi, Jean M, Merghoub, Taha, Chesebrough, Lewis F, Mcdonnell, Autumn S, Gallagher, Jacqueline M, Li, Yanyun, Hollmann, Travis J, Grisham, Rachel N, Erskine, Courtney L, Block, Mathew S, Knutson, Keith L, O’Cearbhaill, Roisin E, Aghajanian, Carol, Konner, Jason A

Volltext